Company Overview

First-of-its-kind company advancing first-in-class retinal gene therapies

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’s venture arm, the Retinal Degeneration Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous inherited retinal diseases.

Our AAV-based gene therapy portfolio, based on the work of scientific founders Dr. Jean Bennett, University of Pennsylvania, and Dr. Eric Pierce, Harvard Medical School and Massachusetts Eye and Ear, addresses inherited retinal diseases for which there is no approved treatment, while creating novel manufacturing scale and efficiencies tailored for producing rare disease therapeutics.

“Opus is bringing together the best instruments of science – the expertise of pioneers in ocular gene therapy, patient voices, committed investors, and strong research – to create important new therapies for patients. This will be our greatest work.”

–Ben Yerxa, Ph.D., acting Opus CEO and the CEO of the Foundation Fighting Blindness and its RD Fund

More Information

For more information, download our corporate presentation